Guanine Releases Sepsis White Paper: “Sepsis Diagnosis at the Speed of Clinical Decision”

Guanine Inc. today announced the release of its new sepsis white paper, “Sepsis Diagnosis at the Speed of Clinical Decision.” The paper presents a time-aligned diagnostic framework designed to deliver actionable insight across the first critical hours of sepsis—integrating host response, pathogen and resistance detection, and treatment response within clinically relevant decision windows.

Sepsis is among the most time-critical emergencies in medicine, yet current diagnostic workflows remain fragmented and slow, often returning definitive answers after key treatment decisions have already been made. Guanine’s white paper outlines a platform strategy intended to help clinicians move from delayed confirmation to time-aligned clarity—supporting earlier risk stratification, faster organism detection, and earlier optimization of antimicrobial therapy.

The paper summarizes how a single platform can support:

• ~20-minute host-response inflammation assessment for early clinical triage
• ~60-minute culture-free pathogen identification and resistance profiling
• ~90–120-minute culture-free phenotyping to inform antimicrobial susceptibility decisions

The Sepsis White Paper is available for download on Guanine’s website.

Guanine Inc. is building a software-defined electrochemical sensing platform for multi-omic diagnostics and real-time phenotyping. The company’s architecture enables highly multiplexed measurement across biological targets from a single sample—designed to support time-critical clinical decisions and scalable OEM diagnostic development.